Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Why buysiders say 2020 could be the year of the CNS

Neurology is back, as buysiders home in on 2020 opportunities

January 11, 2020 12:13 AM UTC
Updated on Jan 18, 2020 at 12:31 AM UTC

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area.

Positive regulatory signals are converging with clinical wins and early-stage scientific advances to put neuroscience back on the radar, after long being viewed as too risky by investors and having been all but abandoned by pharmas...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Biogen Inc.